SBIR/STTR Research Award
Diagnostics to enable Malaria and Neglected Tropical Diseases
Award amount
$221,889Program and phase
SBIR · Phase IAward year
2018Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- HDT BIO CORP
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Z33DCMWXZBK7
- Solicitation number
- Not reported
- Topic code
- NIAID
Research abstract
The role of HDT Bio is to translate discovery into products for infectious diseasesIn this proposal we focus on producing a diagnostic test to aid in the elimination of leprosyWe will develop LepReactan improved and cost effective diagnostic intradermal skin test to permit screening for Mycobacterium leprae infectionLeprosy is a severe neurological disease caused by infection with Mlepraeand development of diseaseas well as person to person transmissioncan be interrupted with early interventionThus prevention of leprosy can only be enabled by sensitive detection of infectionas is done tuberculosisTBusing the tuberculin testWe have identified proteins that hold promise as components for skin test developmentThese proteins demonstrate a high degree of sensitivity for detection of infectionandunlike the tuberculin test for TBhave the potential to form a very specific diagnostic testUsing leprosy patient cellswe will evaluate lead polyproteins that maximize sensitivity without sacrificing specificityAs part of a future IND enabling packagewe will develop scalable manufacturing procedures and evaluate safety and efficacy of formulated proteins using animal modelsThese studies will enable GMP manufacturing and clinical trials for the first safe and defined leprosy skin test
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Development of a RIG-I agonist RNA as a cure for chronic Hepatitis B
- Development of a single-dose self-amplifying RNA vaccine for boosting pre-existing influenza virus immunity, driving B and T cell responses to conserved targets
- Targeting and Imaging Ovarian Cancer with Junction Opener Conjugated-Lipid Iron Oxide Nanoparticles (JOC-LIONs)
- Development of CoroDetecT, a skin test for SARS-CoV-2 infection
- Development of an adaptable RNA vaccine against enterovirus D68 infection for the prevention of acute flaccid myelitis
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
9 SBIR/STTR records share this UEI (2018–2023). Reported award amounts total $2,841,982. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services